samedan logo
 
 
spacer
home > ict > autumn 2017 > three-fold solution
PUBLICATIONS
International Clinical Trials

Three-Fold Solution

Astonishingly, the same four problems that delayed trial
start-ups 20 years ago are still doing so today; very little has
changed. Sponsors, CROs and investigator sites consistently
name redundant training and certification, budgeting
and contracting issues, vendor relations and scheduling
concerns as the top reasons that site activation can take
up to a year (1).

Certainly, these are not the only issues that cause stoppage.
Feasibility studies, regulatory matters and institutional
review board (IRB) approvals play their part, but the ‘big
four’ remain the same. However, stakeholders can embrace
a three-fold solution to speed up trial start dates, which
has the potential to slash site activation times to as little
as 30 days.

The ‘Big Four’

Before turning to the solution, having a clear
understanding of the problems preventing swift site
activation is important.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sean Stanton is Senior Vice President Global Operations at Bioclinica Research Network. He has dedicated the last 25 years of his career to creating successful, high-performing research sites and, to date, has led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics. More than 5,000 trials have been conducted at these sites, leading to over 50 drug approvals, and, in these, he directed recruitment for the screening of 2,000 to 6,000 patients annually. A sought-after industry expert, Sean has brought innovative thinking to research in all aspects of site practice, from purchasing and resourcing to the use of benchmarking and metrics in business planning to guide trial growth.
spacer
Sean Stanton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vaisala launches a completely new probe for the measurement of hydrogen peroxide


More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement